Related Experiment Video
Updated: May 3, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors
1Epworth Hospital, Melbourne, Victoria, Australia; University of Melbourne, Melbourne, Victoria, Australia.
Aims:
Epidermal growth factor receptor inhibitor (EGFRi) therapy for tumor suppression produces significant cutaneous toxicity that may necessitate dose reduction or treatment cessation. This manuscript aims to describe the skin toxicity associated with these agents and equip oncologists with the tools to best manage these patients.
Methods:
A literature review of skin toxicity associated with EGFRi was conducted by a clinical dermatologist experienced in the management of these patients and a management strategy developed for EGFRi skin toxicity
Results:
The sequence of development of EGFRi cutaneous toxicity is predictable. Many skin side effects can be ameliorated by prophylactic therapy. Management of established skin toxicity is complex and needs to be continued throughout the period of EGFRi drug treatment.
Conclusion:
Early referral to a dermatologist experienced in the management of these patients is recommended.
More Related Videos
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Mitogens and the Cell Cycle
Renewal of Skin Epidermal Stem Cells
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

